Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
RESEARCH TOOLSreports
Centessa Pharmaceuticals (CNTA) Stock Price & Analysis
68 Followers
CNTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.96 - $12.45
Previous Close$10.78
Volume120.74K
Average Volume (3M)398.99K
Market Cap
$1.06B
Enterprise Value$866.47M
Total Cash (Recent Filing)$281.34M
Total Debt (Recent Filing)$83.02M
Price to Earnings (P/E)-6.8
Beta0.12
Next Earnings
May 13, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding100,305,850
10 Day Avg. Volume127,590
30 Day Avg. Volume398,989
Standard Deviation0.18
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)4.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.90
Forecast
1Y Price Target
$13.00Price Target Upside20.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Centessa Pharmaceuticals News
PremiumCompany Announcements
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
PremiumCompany Announcements
Centessa Pharmaceuticals Unveils Clinical Data OnlinePremiumPress Releases
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)Bulls Say, Bears Say
Bulls Say
Drug Development ProgressThe promising early signals of efficacy in ALKS's orexin 2 receptor agonist candidate could validate the strong potential of CNTA's similar drug, ORX750, in improving wakefulness over placebo.
Financial MilestonesCNTA's unexpected revenues from out-licensing its CBS004 program, combined with potential for future milestone payments and royalties, signal a strong financial position and growth potential.
Market OutlookThe raised price target for CNTA stock reflects confidence in SerpinPC's market penetration forecasts, suggesting an optimistic outlook for its role in treating hemophilia B.
Bears Say
Competitor Drug IssuesCompetitor drug fitusiran has encountered issues with thromboembolic events, which may affect its market viability.
Drug Development DecisionsTakeda's limitation on the daily dosing of TAK-861 due to potential liver toxicity concerns could have curtailed the drug's efficacy in narcolepsy type 2 trials.
Drug Safety ConcernsSafety events such as visual disturbance and pollakiuria may impact broad uptake of ALKS2680.
---
Ownership Overview
31.32% Insiders
6.72% Mutual Funds
24.24% Other Institutional Investors
37.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $3.96 and its highest was $12.45 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Currently, no data Available
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is May 13, 2024 which is in 20 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on Mar 28, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.488 by $0.108.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -$0.42.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 100,305,850 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.488. Following the earnings report the stock price went down -1.947%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Among the largest hedge funds holding Centessa Pharmaceuticals’s share is Platinum Investment Management. It holds Centessa Pharmaceuticals’s shares valued at 3M.
---
Centessa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (20.59% Upside)
$13.00 (20.59% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 263.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.27%
12-Months-Change
Fundamentals
Return on Equity
-53.01%
Trailing 12-Months
Asset Growth
-18.31%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
---
CNTA Stock 12 Months Forecast
Average Price Target
$13.00
▲(20.59% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Arvinas Holding Company
―
BeiGene
―
Crispr Therapeutics AG
―
Best Analysts Covering CNTA
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+47.10%
assigned a buy rating 14 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +47.10% per trade.
---